Matthew Johnson
Professor of Psychiatry
Data updated
Research Footprint
Matthew Johnson appears in 67 tracked papers (2008–2026) and 1 clinical trial, most studied alongside Psilocybin, LSD and Ayahuasca, across Substance Use Disorders (SUD), Anxiety Disorders and Depressive Disorders.
Most-cited paper: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer (2144 citations).
Frequent co-authors: Roland Griffiths, Albert Garcia-Romeu and Frederick Barrett.
Background & Research
Matthew W. Johnson is an established researcher in human hallucinogen science whose work spans clinical trials, survey-based epidemiology and experimental psychopharmacology. He has co‑authored and led influential studies examining psilocybin‑assisted interventions for substance use disorders (notably tobacco smoking cessation), naturalistic and clinical outcomes following classic psychedelic use (including reductions in alcohol use, psychological distress and suicidality), and dose‑related human effects of non-classic compounds such as salvinorin A. Johnson has collaborated extensively with other prominent investigators in the field to characterise both therapeutic mechanisms and adverse or challenging reactions, and has contributed to safety guidance for human hallucinogen research.
Key Impact
A leading clinical researcher who has advanced evidence on the therapeutic potential and safety of classic psychedelics—particularly psilocybin—for addiction and mental health outcomes through clinical trials, survey research and methodological guidance.
Collaboration Network
43 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Matthew Johnson is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
Founding faculty
A research center within Johns Hopkins University (School of Medicine) that conducts scientific studies on psychedelic compounds, their effects on brain function and consciousness, and their therapeutic potential for mental health conditions.
View stakeholder →